A229500 Share Price Performance
Recent A229500 News & Updates
No updates
NovMetaPharma Co., Ltd. Key Details
Last Reported Earnings
n/a
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
NovMetaPharma Co., Ltd. Competitors
About A229500
- Founded
- 2010
- Employees
- n/a
- CEO
- WebsiteView website
NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibitor and exercise performance enhancement products. The company was formerly known as PNC MetaPharm Co., Ltd. and changed its name to NovMetaPharma Co., Ltd. in May 2015. NovMetaPharma Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -2.5%
- 3 Months: 19.7%
- 1 Year: 13.3%
- Year to Date: 27.4%
Over the last 7 days, the market has dropped 2.5%, driven by a pullback of 8.3% in the Financials sector. In the last year, the market is actually up 13%. Earnings are forecast to grow by 22% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading